Virus-receptor interactions of SARS-CoV-2 spikereceptor-binding domain and human neuropilin-1 b1 domain

Sultan F. Alnomasy
Department of Medical Laboratories Sciences, College of Applied Medical Sciences in Al-Quwayiyah, Shaqra University, Al-Quwayiyah, Riyadh, Saudi Arabia

Abstract

In late 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wahan, China and it causes disease which is known as COVID-19. This infection spreads everywhere in the world, and it leads to an enormous number of death among individuals. The mystery issue about SARS-CoV-2 that appears not to have functions of a hemagglutinin and neuraminidase like other coronaviruses. Angiotensin-converting enzyme 2 (ACE2) is the main surface receptor for entering SARS-CoV-2 into the host cell. This entry process is mediated by binding the SARS-CoV-2 spike receptor-binding domain (RBD) to ACE2. Recently, researchers discover a new receptor responsible for the SARS-CoV-2 entry which is neuropilin-1 (NRP1). So, this work provides afford a knowledge of how the initial interaction between SARS-CoV-2 spike RBD and NRP1 b1 domain may occur. Understanding this interaction would be very necessary for drug design against SARS-CoV-2.

1. Introduction

COVID-19 is disease caused by new emerged virus known as Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This virus is quickly spread to all world countries and causing high mortality and morbidity when compared to MERS-CoV and SARS-CoV (Datta et al., 2020). SARS-CoV-2 infects many cells such as pneumocytes in lungs and epithelial cells in kidney (Farkash et al., 2020). These cells are express angiotensin converting enzyme type 2 (ACE2) that facilitates SARS-CoV-2 entry (Harmer et al., 2002; Soler et al., 2013). The entry of this virus into the host cell is mediated by binding of SARS-CoV-2 spike receptor-binding domain (RBD) to ACE2 (Robson, 2020). This binding leads to the downregulation of ACE2 that may facilitate the progression of COVID-19 from slight to more severe illness such as huge stimulation of platelets and coagulation pathways (Datta et al., 2020). ACE2 may play a critical role in COVID-19 progression. ACE2 is expressed in several tissues such as heart, intestine and kidney (Zhou et al., 2020). SARS-CoV-2 use its surface spike protein to mediate the entry into host cells. This virus comprises a RBD that specifically recognized by its receptor, ACE2 (F. Li et al., 2005; W. Li et al., 2003). Besides ACE2 researchers found that neuropilin-1 (NRP1) plays as an alternative pathway for SARS-CoV-2 entry and also involved in the infection of SARS-CoV-2 (Cantuti-Castelvetri et al., 2020; Daly et al., 2020). NRP1 is a transmembrane receptor and works as a co-receptor for many ligands (Guo et al., 2015; Roy et al., 2017). It composes extracellular regions; CUB domains (a1 and a2), coagulation factor domains (b1 and b2), and a MAM domain (Guo & Vander Kooi, 2015). Of these, SARS-CoV-2 spike protein can bind to the b1 domain of NRP1 (Cantuti-Castelvetri et al., 2020; Daly et al., 2020). Based on these findings, there is no data about the virus-host interactions that identifying the potential binding sites of SARS-CoV-2 spike RBD on NRP1 b1 domain. In this work, an in silico analysis of interaction of SARS-CoV-2 spike RBD with b1 domain of NRP1 was generated for providing knowledge about the binding sites of this coronavirus spike protein on NRP1 b1 domain. So, this computational method would contribute in achieving the aim of understanding about the SARS-CoV-2-NRP1 interactions.

2. Materials and methods

2.1. Sequence information

The wild type of the SARS-CoV-2 genome corresponds to the NCBI reference sequence (NC_045512.2), isolated in December 2019.
2019 from a patient with COVID-19 in Wuhan, China (Lan et al., 2020).

2.2. Preparation

Structures of SARS-CoV-2 spike RBD and structure of the human neuropilin-1 b1 were downloaded from Protein Data Bank (PDB) (www.rcsb.org). The spike structure of SARS-CoV-2 with PDB code 6m0j (Lan et al., 2020) was used as the reference to align other structures of the protein to facilitate further analyses of the docking results. The structure 6m0j is provided as the complex between the spike RBD domain and ACE-2 (i.e., PDBcode_6m0j-ACE2) and without ACE-2 (i.e., PDB code_6m0j-noACE2, 6m0j:E). The structure of the human NRP1 b1 domain was found with PDB code_5JGQ. In the preparation process, we added the hydrogen atoms and optimized the hydrogen bond network with PROPKA (Olsson et al., 2011) considering pH = 7. None of the ionizable residues required manual adjustment of protonation states. The selenomethionine residues were converted to methionines and all non-protein molecules were deleted (waters, ions, cofactors and ligands).

2.3. Docking study and configuration

To perform docking studies, PDB files of 5JGQ and 6m0j:E were submitted to Cluspro 2.0 server (Kozakov et al., 2013; Kozakov et al., 2017; Vajda et al., 2017). Cluspro 2.0 was generated several
docking models, then ProQdock was used to check the quality of the docking models (Basu et al., 2016).

3. Results

3.1. Docking model of interaction of SARS-CoV-2 spike RBD and human neuropilin-1 b1 domain

The database of PDB was explored for the 3D structure of SARS-CoV-2 spike RBD, the accession number 6m0j:E was found. The structure of 6m0j:E was revealed by X-ray diffraction (Lan et al., 2020). After that, PDB database was also searched for the 3D structure of NRP1 b1 domain, PDB file with code 5JGQ was found. Thereafter, work was carried out to identify binding sites of SARS-CoV-2 spike RBD on NRP1 b1 domain. Cluspro 2.0 was created several docking models. These models were ranked based on their quality score by ProQdock. The top-scored docking model was selected in this work (Fig. 1A). The score of modeling confidence was used to judge the reliability of this docking model, and its overall global quality score is 0.92520. This score showed that this docking has a more confident model. This docking model showed that there are potential sites of binding of SARS-CoV-2 spike RBD on NRP1 b1 domain (Fig. 1B). In this model, many locations of interaction were identified as potential binding sites for SARS-CoV-2 spike RBD on the b1 domain of NRP1. GLN380, ASP389, TYR322, ARG323, TRP325, GLN327, ASP329, LYS359, ASP361 residues were identified as potential binding sites on NRP1 b1 domain for SARS-CoV-2 spike RBD (Fig. 1B). Also, there is a contact between GLN380, ILE305, PHE294, ALA 30 of SARS-CoV-2 spike RBD domain and ARG402, ARG306, LYS307 of NRP1 b1 domain (Fig. 1B). This docking study showed several important binding sites for SARS-CoV-2 spike RBD on human host NRP1 b1 domain. These data could be contribute in reaching the goal for treatment development against SARS-CoV-2 through providing more information about binding sites of the interaction of SARS-CoV-2 spike RBD with human host NRP1 b1 domain.

4. Discussion

The SARS-CoV-2 is causative agent for the COVID-19 that emerged in Wuhan, China in December 2019 and leading to an uncontrollable global outbreak. COVID-19 is associated with severe respiratory illness, fever, and pneumonia (Lai et al., 2020). The mechanism of SARS-CoV-2 entry into host has been extensively studied with ACE2 (Datta et al., 2020; Lan et al., 2020). Recently, scientists found that NRP1 is potential another pathway for SARS-CoV-2 entry and is implicated in the progression of COVID-19 (Cantutti-Castelvetri et al., 2020; Daly et al., 2020). The studying of the interaction of SARS-CoV-2 spike RBD with NRP1 b1 domain is conducted in this work due to there are limited studied about this interaction. So, docking study is carried out for this purpose. Binding sites of SARS-CoV-2 spike RBD with its NRP1 receptor that presents on surface with interacting amino acids; GLN380, ASP389, TYR322, ARG323, TRP325, GLN327, ASP329, LYS359, ASP361. Bound structure of SARS-CoV-2 spike RBD with NRP1 b1 domain is considered as target for drug discovery to treat SARS-CoV-2 infection.

5. Conclusions

The bioinformatics analyses indicated the possible binding specificity of SARS-CoV-2 spike RBD and NRP1 b1 domain. Data predict how the initial binding of SARS-CoV-2 spike RBD to NRP1 b1 domain may happen. These data are necessary for drug-design perspective.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

Basu, Sankar, Walliner, Bjorn, 2016. Finding correct protein-protein docking models using ProQDock. Bioinformatics (Oxford, England) 32 (12), i262–i270. https://doi.org/10.1093/bioinformatics/btw257.

Cantutti-Castelvetri, Ludovico, Ojha, Ravi, Pedro, Liliana D., Djambjaj, Minou, Franz, Jonas, Kuvanen, Savi, Simons, Mikael, 2020. Neurophin-1 facilitates SARS-CoV-2 cell entry and infectivity. Science eabd2985. https://doi.org/10.1126/science.abd2985.

Daly, James L., Simonetti, Boris, Klein, Katja, Chen, Kai-En, Williamson, Maia Kavanagh, Antônio-Págaro, Carlos, Yamauchi, Yohe, 2020. Neurophin-1 is a host factor for SARS-CoV-2 infection. Science eabd3072. https://doi.org/10.1126/science.abd3072.

Datta, Prasun K., Liu, Fengming, Fischer, Tracy, Rappaport, Jay, & Qin, Xuebin, 2020. SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV2–SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy. Theranostics, 10(16), 17446–17446. doi: 10.1710/thno.48076.

Farkash, E.A., Wilson, A.M., Jentzen, J.M., 2020. Ultrastructural evidence for direct renal infection with SARS-CoV-2. J. Am. Soc. Nephrol. 31 (8), 1683–1687. https://doi.org/10.1681/asn.2020040432.

Guo, H.F., Vander Rooi, C.W., 2015. Neurophin functions as an essential cell surface receptor. J. Biol. Chem. 290 (49), 29120–29126. https://doi.org/10.1074/jbc.m115.668727.

Harmer, D., Gilbert, M., Borman, R., Clark, K.L., 2002. Quantitative mRNA expression profiling of ACE 2, a novel homolog of angiotensin converting enzyme. FEBS Lett. 532 (1–2), 107–110. https://doi.org/10.1016/s0014-5793(02)03640-2.

Kozakov, D., Beglov, D., Bohnud, T., Mottarella, S.E., Xia, B., Hall, D.R., Vajda, S., 2013. How good is automated protein docking? Proteins 81 (12), 2159–2166. https://doi.org/10.1002/prot.24403.

Kozakov, D., Hall, D.R., Xia, B., Porter, K.A., Padhony, D., Yueh, C., Vajda, S., 2017. The ClusPro web server for protein-protein docking. Nat. Protoc. 12 (2), 255–278. https://doi.org/10.1038/nprot.2016.169.

Lai, Chih-Cheng, Ko, Wen-Chien, Lee, Ping-Ing, Jean, Sho-Shin, & Hsué, Po-Ren, 2020. Extra-respiratory manifestations of COVID-19. Int. J. Antimicrobial Agents 56 (3), 106024–106024. doi:10.1016/j.ijantimicag.2020.106024.

Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., Wang, X., 2020. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 581 (7807), 215–220. https://doi.org/10.1038/s41586-020-2180-5.

Li, F., Li, W., Farzan, M., Harrison, S.C., 2005. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science 309 (5742), 1864–1868. https://doi.org/10.1126/science.1116480.

Li, W., Moore, M.J., Vasilieva, N., Sui, J., Wong, S.K., Berne, M.A., Farzan, M., 2003. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426 (6965), 450–454. https://doi.org/10.1038/nature02145.

Olsson, Mats H.M., Sandergaard, Chresten R., Rostkowski, Michal, Jensen, Jan H., 2011. PROFPKA3: Consistent treatment of internal and surface residues in empirical pKa predictions. J. Chem. Theory Comput. 7(12), 525–537. doi:10.1021/ct100578z.

Robson, B., 2020. COVID-19 Coronavirus spike protein analysis for synthetic vaccines, a peptidomimetic antagonist, and therapeutic drugs, and analysis of a proposed achilles’ heel conserved region to minimize probability of escape mutations and drug resistance. Comput. Biology Med., 121, 103749-103749. doi:10.1016/j.compbiomed.2020.103749.

Roy, S., Bag, A.K., Singh, R.K., Talmadge, J.E., Batra S.K., Datta, K., 2017. Multifaceted role of neurophins in the immune system: potential targets for immunotherapy. Front. Immunol. 8, 1228. https://doi.org/10.3389/fimmu.2017.01228.

Soler, M.J., Wysocki, J., Battie, D., 2013. ACE2 alterations in kidney disease. Nephrol. Dial. Transplant. 28 (11), 2987–2997. https://doi.org/10.1093/ndt/gft200.

Vajda, Sandor, Yueh, Christine, Beglov, Dmitri, Bohnud, Narrissa, Motarella, Scott E., Xia, Bing . . . Kozakov, Dima, 2017. New additions to the ClusPro server motivated by CAPRI. Proteins 85 (3), 435–444. https://doi.org/10.1002/prot.25219.

Zhou, P., Yang, X.L., Wang, X.G., Hu, B., Zhang, L., Zhang, W., . . . Shi, Z.L., 2020. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579 (7798), 270–273. https://doi.org/10.1038/s41586-020-2012-1.